**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 10316**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (20): Gastrointestinal surgery

**Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor**

Alagusundaramoorthy SS *et al.* Liver metastases from neuroendocrine tumors

Sayee Sundar Alagusundaramoorthy, Roberto Gedaly

**Alagusundaramoorthy Sayee Sundar, Gedaly Roberto,** Department of Surgery, University of Kentucky, College of Medicine, Lexington, KY 40536, United States

**Author contributions:** Both authors were involved in doing an extensive review of the literature, editing and writing of this manuscript.

**Correspondence to: Roberto Gedaly, MD, Chief,** Division of Transplantation, University of Kentucky**,** 800 Rose Street, Room C453, Lexington, KY 40536, United States. [rgeda2@uky.edu](mailto:rgeda2@uky.edu)

**Telephone:** +1-859-3234661 **Fax**: +1-859-3234661

**Received:** March 26, 2014 **Revised:** April 24, 2014

**Accepted:** June 12, 2014

**Published online:**

**Abstract**

Neuroendocrine tumors (NET) are a heterogeneous group of cancers, with indolent behavior. The most common primary origin is the gastro-intestinal tract but can also appear in the lungs, kidneys, adrenals, ovaries and other organs. In general, NET is usually discovered in the metastatic phase (40%-80%). The liver is the most common organ involved when metastases occur (40%-93%), followed by bone (12%-20%) and lung (8%-10%).A number of different therapeutic options are available for the treatment of hepatic metastases including surgical resection, transplantation, ablation, trans-arterial chemoembolization, chemotherapy and somatostatin analogues. Recently, molecular targeted therapies have been used, usually in combination with other treatment options, to improve outcomes in patients with metastases. This article emphasizes on the role of surgery in the treatment of liver metastases from NET.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words**: Neuroendocrine Tumors, Liver Metastases, Hepatectomy, Liver Transplantation

**Core tip:** This is an extensive review of the literature focusing on the role of surgery (resection and transplantation) and the recently published literature in the treatment of liver metastases from neuroendocrine tumors.

Alagusundaramoorthy SS, Gedaly R. Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor. *World J Gastroenterol* 2014; In press

**INTRODUCTION**

Neuroendocrine tumors are a heterogeneous group of neoplasms, with indolent patterns of growth and bizarre hormonal symptoms. Although sporadic, a small group of patients are affected by Multiple Endocrine Neoplasia type 1(MEN 1). They include carcinoid tumors, pancreatic islet cell tumors, paragangliomas, pheochromocytomas and medullary thyroid carcinoma. These tumors can be broadly classified into two categories as high grade malignant neuroendocrine carcinomas with characteristic small cell, anaplastic or undifferentiated appearance in light microscopy and low grade malignant neuroendocrine carcinomas with characteristic, well differentiated histologic features that arise primarily in the gastro-intestinal tract but also appear in the lungs, kidneys and ovaries. In general, NET is usually discovered in the metastatic phase (40%-80%). The liver is the most common organ involved when metastases occur (40%-93%), followed by bone (12%-20%) and lung (8%-10%). Liver metastases from NET is the main cause of death with 90% of the patients affected having multifocal and bilateral metastases[1-4].

A number of different therapeutic options are available for the treatment of hepatic metastases including surgical resection, transplantation, transarterial chemoembolization, radiofrequency ablation, chemotherapy and somatostatin analogues. The low proliferative rate of NET makes cytotoxic chemotherapeutic agents ineffective in controlling the growth and spread of the majority of these lesions. The 5 year survival rate in untreated patients is approximately 30%. The use chemo-therapeutic agents prolong survival by only a mean of 12-24 mo. Somatostatin analogues remain the priority of treatment of functioning syndromes with unresectable metastases[5,6]. The standard treatment for neuroendocrine tumors is surgery even in the presence of hepatic metastases. Some experts have suggested that resection should be considered if resection of 90% or more of the tumor volume is feasible. The use of image guided ablative techniques has served as an adjunct to surgery in selected patients to improve patient symptoms and overall survival. Although all these approaches are associated with favorable response rates, metastatic NET is ultimately a fatal disease with high rates of tumor recurrence after treatment. The recurrence rate is high even in patients with unilobar disease with no evidence of extra-hepatic metastases. Surgical resection provides excellent disease control with an overall survival rate of 47%-92%. Resolution of symptoms is possible in more than 90% of patients with very low operative mortality[7,8]. Total hepatectomy and Liver transplantation has been advocated in selected patients with bilateral unresectable symptomatic liver metastases. There has been an increasing interest in determining the role of liver transplantation in treating these patients. Recent evidences suggested that 5 year overall survival after liver transplantation for unresectable Liver metastasis can be as good as 60%-80% with improved patient selection and adjustments in the clinical-pathological definition of stages[9,10].

The aim of this study is to do an extensive review of the existing literature on the use of liver resection and transplantation in patients with liver metastases from NET.

**ROLE OF SURGERY**

Surgical resection is considered the best treatment option for patients with hepatic metastases from neuro-endocrine tumors. Resection is feasible only when 90%-100% of the tumor metastases are amenable to resection[29-33]. Soreide et al compared the overall survival in patients who underwent surgical resection versus conservative management and found a median survival of 216 mo in resected patients with 48 mo in the unresected patients. However, relatively long survival rates have been reported in untreated patients commonly due to the indolent nature of these tumors[11].

The various strategies of surgical resection have been suggested such as resection with curative intent and palliative cyto-reductive surgery to reduce local and systemic effects of the disease. Curative resection of liver metastases is possible only in 10%-25% of the patients. In a significant number of patients, residual tumor is left behind which is associated with disease progression. Elias *et al*[28]suggested that the reason behind high incidence of intra-hepatic recurrence is related to underestimated disease by current imaging techniques in close to 50% of patients. Mayo *et al*[29] reported an R0 resection rate of only 53.7% with an R1 resection rate of around 33%. Saxena *et al*[19] did a systematic review of all the 29 studies conducted between 1990 and 2009 and found a median rate of 63% R0 resection in a total of 1469 patients who underwent liver resection of hepatic metastases from neuro-endocrine tumors. Interestingly, the median overall progression free survival was only 21 mo and disease free survival (DFS) median at 5 and 10 years of 29% and 1% respectively.

Palliative cytoreduction is indicated in patients with the main intent to control the systemic and local tumor related symptoms. A recent study demonstrated an improvement of symptoms in 95% of the patients after cyto-reduction. The rationale behind this approach is that removal of more than 90% of the tumor bulk allows a significant clinical improvement otherwise not achievable by other non-surgical approaches[31].

Liver resection of metastases from NET has an overall survival rate in the range of 47%-92% with resolution of symptoms in more than 90% of the patients with very low operative mortality (Table 1). Nagorney *et al*[4] proposed that surgical resection in metastatic NETs is indicated if the primary tumor is resectable and if 90% of the liver metastases are resectable and/or are amenable for ablation. Their overall survival is 75% with this approach. However, in the same group disease free survival was only 15% indicating again the high incidence of recurrence after hepatectomy. Due to these low rates of DFS and high rates of recurrence, several experts have questioned the role of surgical resection in these patients. A study from the Mayo Clinic reported a 5 year overall survival for patients treated by surgical resection and intra-arterial therapy be 74% and 30% respectively with also an increased median survival in the surgically resected group of 123 mo versus only 34 mo for the Intra-arterial therapy. They also reported a 10 year survival rate of 51% post-surgical resection but very high recurrence rates after resection at 5 and 10 years[16]. Glazer *et al*[21] also reported similar results with 5 year survival of 77% in patients undergoing hepatectomy for NET metastases.

Saxena *et al*[19] also reported in a review of the literature a median perioperative mortality of 0%, a surgical morbidity of 23% and a median overall survival of 70.5% at 5 years and 42% at 10 years. These findings support aggressive surgical resection if feasible.

A study by Glazer *et al*[21] from the Mayo Clinic reported 60 among the initial 159 patients underwent repeated surgery for recurrence with an overall survival was higher than 60%[18,21]. Although the data suggests a benefit from the second surgery, the selection of patients should be carefully done based on a number of factors including a thorough assessment of the perioperative risk. Ablation is frequently used with surgical resection as the metastases are frequently multifocal and bilateral. It has been reported that ablation is performed in at least one-fifth of the patients undergoing surgery for treatment of NET metastases[43]. The role of ablation versus resection was studied by Osborne *et al*[15] reporting a 5 year overall survival of 35% and 78% respectively. A similar study by Yao *et al*[14] reported similar overall survival of 70% and 40% after hepatectomy *vs* ablation respectively]. Elias et al reported an improved overall survival of 84% at 3 years with disease free survival of 50% when combining surgical resection and ablation[28]. Hence, ablation can be used as an adjunct with hepatic resection as initial treatment and to treat local recurrence[43].

Although extra-hepatic disease has been shown to have a worst prognosis in several series, patients with stable limited extra hepatic involvement can be considered for surgery, especially in symptomatic patients based on the underlying tumor biology and grade.

**ROLE OF LIVER TRANSPLANTATION**

Until recently, clear evidence was lacking regarding the role of Orthotropic Liver Transplantation in the treatment of unresectable liver metastases from NET (Table 2). The inconsistency in the data available can be attributed to the low incidence of the disease leading to a small sample size and a wide variety of treatments and algorithms offered in the initial stages. Considerable controversy exists due to the absence of adequate available data comparing transplantation for unresectable liver metastases to other treatment modalities. Also, transplantation for any malignancy should generate a sustained response with satisfactory 5 year overall survival rates to be considered an option[37,42]. Mazzaferro and colleagues emphasized the importance of patient selection. He initially proposed a selection criteria for patients undergoing transplantation for hepatocellular carcinoma which has been used now for several years in transplant centers around the world. More recently and based in his previous results with HCC patients, the group from Milan has suggested selection criteria for potential candidates for LT with diagnosis of liver metastases from NET. They proposed that age less than 55, Ki-67 proliferation index of less than 10%, primary that is limited to tumors with portal venous drainage, no other spread to a secondary organ other than the liver, and metastatic disease involving no more than 50% of the hepatic volume. This criteria was based on limited number of patients and has not been significantly validated by other transplant groups[39].

However, using this approach they reported excellent results with a 5 year survival rate close to 90%. These results are significantly better than those obtained in similar patients undergoing conservative management. They also observed that liver transplantation was associated with a recurrence free survival of about 80% at 5 years, which is significantly higher compared to less than 50% associated with the non-transplant strategy[40].

Other groups have obtained comparable overall survival rates (70%-90%). Olausson et al transplanted 10 patients with expanded criteria with higher proliferation rate, large tumor burden and increased age but were still able to show a 90% 5 year survival[41]. Le treut *et al*[10] did a systematic review of the European Liver Transplant Registry and observed the following; three month postoperative mortality was 10%, after 5 years of LT the overall survival was 52% and disease free survival was 30%. The most significant predictors of poor outcome were other major procedure in addition to LT, poor tumor differentiation and liver size and involvement. The highest risk factor for peri-operative mortality was upper abdominal exenteration at the time of Liver transplantation. They also observed that since 2000, the 5-year survival has increased to 59% in relation to the recent advances in patient selection, surgical techniques, increased wait time for stabilization of the disease and possibly the use of pre-transplant treatments. They also suggest that a multi-stage approach for the removal of primary prior to LT is associated with an improved overall survival.

It has been reported that overall 5 year survival rates of untreated NET is around 35% at 5 years with a median survival of 39 months. It is interesting to note that although Liver transplantation is usually performed after all other treatment options have been exhausted, the 5 year overall survival rate from the time of diagnosis was 73% in this large European series. Although it is very difficult to compare studies using different treatment options and without standardizing of patients characteristics it seems to be some evidence that selected patients may benefit from LT.

Our group, in a systematic review analysis of the UNOS database found an overall survival after transplantation for liver metastases of NET not significantly different than Hepatocellular carcinoma which is the second most common indication for liver transplantation in the United States after 2010. It is important to remember that HCC patients are usually transplanted within certain criteria (Milan, UCSF, *etc.,*) while there is not a clear selection criteria for patients with liver metastases from NET. However, tumor recurrence rate was 31% which is higher than the rates in the range of 10%-15% reported in patients undergoing transplantation for HCC. We performed an analysis of survival by quartile of wait-time and found the longer the wait the better the overall survival in these patients. The mean wait time was around 60 d in the UNOS series. Patients who underwent transplantation for liver metastases of NET have significantly better survival if they have to wait more than 60 d. We proposed that patients should wait for disease stability before being considered for LT[9].

Guyen *et al*[38] also conducted a review of the UNOS database and found a significant increased 5 year survival from 49.2% to 57.8% compared to the pre MELD era after the introduction of the MELD/PELD score in 2002. However the overall survival of patients transplanted for non-malignant indications was 73.7%, still significantly higher than patients transplanted for malignant indications. They also found a deleterious effect with elevated serum creatinine in the donor, elevated serum bilirubin in the recipient and a protective effect with normal serum albumin in the recipient at time of transplant.

The role of transplantation as a salvage or curative procedure in this patient population is still under debate. Available data suggested that transplantation can offer a significant survival benefit when patients are selected properly. LT can therefore be used as a treatment option in patients who have stable disease, well differentiated unresectable symptomatic or asymptomatic liver metastases of NET, confined to the liver and in which the removal of the primary tumor was performed before the liver transplant procedure. Prospective multi-centric studies are still warranted to validate a specific selection criteria for liver transplantation.

**IMAGE GUIDED ABLATIVE TECHNIQUES FOR THE TREATMENT OF LIVER METASTASES FROM NET**

Ablation therapy has been extensively used to treat liver metastases from NET (Table 3). Some experts believe that aggressive ablative techniques with reduction in tumor volume of more than 90% should provide good results similar to surgical resection. RFA of oligonodular liver metastases of less than 5 cm can result in symptomatic response in 70%-80% of patients with hormonal syndromes. The role of RFA in symptom control, reducing octreotide dependence and in the treatment of metastases that are amenable to surgical resection has been well documented in the literature[43-47,57]. Ablation treatment provides complementary treatment in the operative management of patients with bilobar or extensive liver disease. Only a small number of patients are eligible for complete resection at the time of diagnosis either due to extensive tumor burden, critical location of the metastases within the liver and the presence of significant extrahepatic disease. The incorporation of RFA as an adjunct to surgical resection has led to an increase in the number of patients eligible for resection of hepatic metastases from neuroendocrine metastases. Nagorney et al reported a 5 year survival of 80% and 10 year survival of 59% with if more than 90% of the intrahepatic disease can be resected or ablated[43].

In completely inoperable patients due to co-existing medical conditions, percutaneous ablation can be safely used to treat hepatic metastases. This reduces the hepatic tumor burden and may improve the patient survival (Table 3). Percutaneous ablation can also be used to treat recurrences in previously resected patients. Microwave ablation is being used in some centers as an alternative to RFA[52]. Microwave (MWA) can reduce the time required to ablate this lesions and could also be used in metastases closer to major hepatic vasculature where RFA might not be that effective due to the heat sink effect. Martin et al., reported a success rate of 90% with MWA for hepatic metastases from NET[45]. Gravante *et al*[56] did a systematic review and found no viable cells as far as 6cm away from the center of ablation in 93% of cases treated with MWA. There is no available data comparing the effectiveness of RFA to MWA for the treatment of hepatic metastases form NET.

**INTRA-ARTERIAL THERAPIES**

NET liver metastases are highly vascular and amenable to ischemia and necrosis if blood supply is occluded. The blood supply of these metastases is mostly dependent on hepatic artery for their oxygenation[69-71].

The vascular blockade can be accomplished through bland embolization of the Hepatic Artery (HAE), chemo-embolization (HACE), or embolization with drug eluting beads (DEB-HACE) (Table 4). Chemoembolization involves the use of chemo-therapeutic agents such as doxorubicin, cisplatin, mirplatin, gemcitabine, streptozocin, mitomycin C, 5-FU mixed with an embolic agent like ethiodized oil or lipoidol with the slurry then infused. Potential contraindications to embolization include occlusion of the portal vein, severe liver dysfunction and presence of a biliary anastomosis. Vascular occlusion can achieve reduction of hormonal symptoms, reduced tumor burden and improved survival in patients not candidates for surgical resection. Sequential embolization of hepatic artery can offer prolonged palliation for responsive patients even if performed later in their course of the disease. Clinical response rates of over 90% have been reported with a median survival ranging 3 years with a progression free survival of 18 months[72,73,75,78-80] (Table 4). A small randomized trial by Pitt *et al*[27] comparing TAE versus TACE in all NETs has shown no difference in time to progression (25.5 *vs* 25.7 mo). DEB-HACE aims for a durable and less toxic impact from chemotherapy by loading larger embolic beads with a drug that is released over a period of time with less systemic exposure and toxicity thereby. Bhagat *et al*[31] reported a 90% symptom control in 6 months using drug eluding beads, however their trial was interrupted by a higher than anticipated rate of bilomas. Ho et al reported that even in patients with unresectable extra-hepatic disease, liver directed embolization can be done with a post-embolization survival benefit and 80% symptomatic improvement[64].

Recently, radio-embolization using Yttrium 90 microspheres in patients with inoperable or even disseminated disease have been utilized to treat NET metastases even in patients with previous TAE/TACE[74,76]. They deliver a form of internal radiation therapy to selected vascular territory. Contra-indications to this therapy are a large tumor burden and severe liver dysfunction with vascular involvement such as portal vein thrombosis. Median survival in this approach varies from 36 to 70 mo with tumor grade, radiographic response to treatment and presence of extra-hepatic disease being the most significant prognostic factors reported. Most causes of death were due to disease progression outside the liver[58,60,61]. Evidence is lacking comparing the effectiveness of radio-embolization to other modes of intra-arterial embolization. The advantage of radio embolization is that the hospital stay is usually shorter and procedures are fewer when compared to HAE/HACE. Also repeated radio-embolization to treat recurrence is possible as the microspheres are smaller and leave the vascular supply patent the so called pruning effect. Complications including radiation pneumonitis, gastritis, etc have also been reported in the literature. Hence pre-procedural scans with 99 mTc labeled macro aggregate albumin is necessary to rule out major pulmonary shunting[58,60].

**SYSTEMIC THERAPIES**

Somatostatin analogues are used for symptom relief in most patients because over 70% of NETs express somatostatin receptors that can be targeted. Octreotide provides symptomatic benefit in about 85% of patients and biochemical response in 70% of patients within weeks of commencement[81]. Carcinoid syndromes due to the release of serotonin intra-procedurally can be overcome by the pre and post procedural administration of Octretotide. Somatostatin analogues also have an anti-proliferative property as they lengthen the time of tumor progression as compared to placebo injections. This benefit is seen both in functionally active as well as inactive tumors[82]. The PROMID study group conducted a double blind randomized phase III placebo controlled trial for Octreotide LAR and found the median survival for patients receiving Octreotide LAR to be 14.3 mo *vs* 6 mo on the placebo arm. Octreotide can be safely and effectively used in patients in whom primary has been resected and have a low hepatic tumor burden[6,83– 85].

Interferon alpha has also been used in place of somatostatin analogues for some symptomatic response but no clear survival benefit or reduction in tumor size and progression has been established. It may be an alternative for patients who have failed therapy with somatostatin analogues[94,95].

The role of systemic chemotherapy is highly variable in treating NETs because of the disparities in the underlying tumor biology, differences in the endpoints that are measured and the regimens used. Chemotherapeutic agents usually target the actively dividing cells and tumors with a high proliferation index are more susceptible to chemotherapy. Poorly differentiated tumors with a high proliferation index are more susceptible to chemotherapy than well differentiated tumors with a low proliferation index. The overall response to chemotherapy varies from 25%-78% with progression free periods between 4-22 mo. Hence, patient selection and individualized chemotherapy are required to maximize response and prevent hepatic toxicity. Response can be measured radiologically by decreased or stabilized tumor size, improved biochemical markers and improvement in the overall quality of life[86-98].

No difference has been shown to exist between the new agents as monotherapy such as paclitaxel, gemcitabine[97], temozolomide[92],topotecan[86] and the older ones like streptozocin[88,93,96],dacarbazine[87], 5FU[93,96] and doxorubicin[93]. Traditionally a combination of two agents to treat has been shown to have a higher response rate and improved overall survival when compared to a single agent[5]. Response rates for the combination of streptozocin and doxorubicin vary from 30%-70% emphasizing the importance of patient selection and individualization of treatment[91]. Recently a combination of capecitabine and temozolomide has been shown to have a progression free survival of 70% at 18 mo and a 2 year survival of 92%[90]. A triplet combination of streptozocin, doxorubicin and 5 FU in 84 patients with locally advanced or metastatic pancreatic NETs was shown to have an overall response rate of 39%. The standard chemotherapeutic regimen continues to be streptozocin based due to the absence of randomized trials evaluating the efficacy of other regimes. A combination of cisplatin and etoposide has been used to treat anaplastic NETs. The prognosis remains poor in this group with a 2 year survival at 20%-30%[89].

NETs that express somatostatin receptor subtype 2 showing an uptake in octreotidescintigraphy or somatostatin based PET imaging can be treated with beta emitting 90 Y and 177 Lu labeled somatostatin analogues. This presents a therapeutic option in patients with otherwise systemic inoperable and drug resistant disease having a survival ranging from 40-72 mo. The use of these treatments stabilizes the disease with a time to progression of 40 mo and response rates of up to 30%. With this method there is a delivery of the radio-isotope selectively to all the to both intra-hepatic and extra-hepatic somatostatin avid metastases[99-105]. Adverse effects including radiation induced bone marrow toxicity, nephrotoxicity and gastro intestinal disturbances have been reported. The use of alpha emitting isotopes with higher cytotoxicity than the beta emitting isotopes such as Act 225 and addition of radio-sensitizers like gemcitabine and capecitabine may improve clinical outcomes[99,103].

Patients with a positive MIBG uptake scan can be treated with 131 I-MIBG therapy. This is associated with an improved overall survival with marked improvement in clinical symptoms as well as biochemical markers[107].

The evolution of molecular genetics and targeting the molecular mechanisms involved in the pathogenesis of NETs have resulted in newer drugs that target the intra-mural pathways in these tumors. Liver metastases from NETS show a significantly up regulated VEGF C expression which may be involved in their progression and can be used as a potential target[109,110]. Some of the recent drugs that have been implicated in the treatment of NETs include Sunitinib-a multi targeted tyrosine kinase inhibitor having activity against a wide range of molecular pathways including VEGF derived and platelet derived growth factor receptors[106],Everolimus–an oral inhibitor of mammalian target of rapamycin (mTOR)[112] and Bevacizumab-a ligand monoclonal antibody directed against VEGF[108,111]. Adverse effects such as diarrhea, vomiting, fatigue, stomatitis and nausea have been reported in all these therapies. The median progression free survival was 11.4 mo for sunitinib and 11.0 mo for everolimus versus 4.6 mo and 5.5 mo on placebo respectively. There are also reports of clinical benefit when these are combined with existing chemotherapy treatments. Targeted therapy is appropriate in patients who have a progressive disease where tumor stability would yield a clinical benefit.

**CONCLUSION**

The care of patients with hepatic metastases of neuroendocrine tumors should involve a multi-disciplinary team of surgeons, interventional radiologists and nuclear medicine physicians to assess the potential of various therapies including liver directed and systemic therapies. The first step in management would be assessing the tumor biology, grade and considering the patient for hepatic metastasectomy which is associated with the best long term outcome and overall survival. Transplantation should be considered in selected patients with abdominal portal vein drained NET in which primary lesion has been resected, less than 50% of liver involvement, no extrahepatic disease and in those with disease stability for a period of time prior to surgery. The role of transplantation for the treatment of hepatic metastases from NET is still to be defined. The combination of hepatectomy plus ablation could be recommended specially in symptomatic patients and if more than 90% of the tumors can be resected or ablated. Radio or chemoembolization should have a role in those patients not candidates for surgery or ablation alone or combined. Somatostatin analogues should be used for symptom control and also for their anti-proliferative effect. Molecular targeted therapies can be used before, during or after conventional chemotherapy. An individualized treatment approach to patient care is needed given the breadth of symptoms and disease, the lack of a validated treatment pathway, as well as the indolent nature of the disease. Future trials are needed to still validate the role of specific therapies in the management of this difficult neoplasm.

**REFERENCES**

1 **Sutcliffe R**, Maguire D, Ramage J, Rela M, Heaton N. Management of neuroendocrine liver metastases. *Am J Surg* 2004; **187**: 39-46 [PMID: 14706584 DOI: 10.1016/j.amjsurg.2003.04.007]

2 **Sarmiento JM**, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. *J Am Coll Surg* 2003; **197**: 29-37 [PMID: 12831921 DOI: 10.1016/S1072-7515(03)00230-8]

3 **Que FG,** Nagorney DM, Batts KP, Linz LJ, Kvols LK. Hepatic resection for metastatic neuroendocrine carcinomas. *Am J surg* 1995; **169**: 36-42; discussion 42-33 [PMID: 7817996 DOI: 10.1016/S0002-9610(99)80107-X]

4 **Que FG**, Sarmiento JM, Nagorney DM. Hepatic surgery for metastatic gastrointestinal neuroendocrine tumors. *Adv Exp Med Biol* 2006; **574**: 43-56 [PMID: 16836240 DOI: 10.1007/0-387-29512-7\_7]

5 **Bajetta E**, Ferrari L, Procopio G, Catena L, Ferrario E, Martinetti A, Di Bartolomeo M, Buzzoni R, Celio L, Vitali M, Beretta E, Seregni E, Bombardieri E. Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours. *Ann Oncol* 2002; **13**: 614-621 [PMID: 12056713 DOI: 10.1093/annonc/mdf064]

6 **Rinke A**, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder J, Arnold C, Gress T, Arnold R. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. *J Clin Oncol* 2009; **27**: 4656-4663 [PMID: 19704057 DOI: 10.1200/JCO.2009.22.8510]

7 **Grazi GL**, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, Mazziotti A. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. *Hepatogastroenterology* 2000; **47**: 481-486 [PMID: 10791218]

8 **Nave H**, Mössinger E, Feist H, Lang H, Raab H. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. *Surgery* 2001; **129**: 170-175 [PMID: 11174710 DOI: 10.1067/msy.2001.110426]

9 **Gedaly R**, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, Hundley JC. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. *Arch Surg* 2011; **146**: 953-958 [PMID: 21844436 DOI: 10.1001/archsurg.2011.186]

10 **Le Treut YP**, Grégoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, Castaing D, Soubrane O, Boillot O, Mantion G, Homayounfar K, Bustamante M, Azoulay D, Wolf P, Krawczyk M, Pascher A, Suc B, Chiche L, de Urbina JO, Mejzlik V, Pascual M, Lodge JP, Gruttadauria S, Paye F, Pruvot FR, Thorban S, Foss A, Adam R. Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection: a 213-case European liver transplant registry study. *Ann Surg* 2013; **257**: 807-815 [PMID: 23532105 DOI: 10.1097/SLA.0b013e31828ee17c]

11 **Søreide O**, Berstad T, Bakka A, Schrumpf E, Hanssen LE, Engh V, Bergan A, Flatmark A. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. *Surgery* 1992; **111**: 48-54 [PMID: 1728075]

12 **Chen H**, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? *J Am Coll Surg* 1998; **187**: 88-92; discussion 92-3 [PMID: 9660030 DOI: 10.1016/S1072-7515(98)00099-4]

13 **Ahmed A**, Turner G, King B, Jones L, Culliford D, McCance D, Ardill J, Johnston BT, Poston G, Rees M, Buxton-Thomas M, Caplin M, Ramage JK. Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. *Endocr Relat Cancer* 2009; **16**: 885-894 [PMID: 19458024 DOI: 10.1677/ERC-09-0042]

14 **Yao KA**, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, Benson AB, Rao S, Joehl RJ. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. *Surgery* 2001; **130**: 677-82; discussion 682-5 [PMID: 11602899 DOI: 10.1067/msy.2001.117377]

15 **Osborne DA**, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, Yeatman TJ, Carey L, Duhaine L, Kvols LK. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. *Ann Surg Oncol* 2006; **13**: 572-581 [PMID: 16511671 DOI: 10.1245/ASO.2006.03.071]

16 **Mayo SC**, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, Clark Gamblin T, Celinski SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Arrese D, Ferrero A, Schulick RD, Choti MA, Geschwind JF, Strub J, Bauer TW, Adams RB, Aldrighetti L, Mentha G, Capussotti L, Pawlik TM. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. *Ann Surg Oncol* 2011; **18**: 3657-3665 [PMID: 21681380 DOI: 10.1245/s10434-011-1832-y]

17 **Coppa J**, Pulvirenti A, Schiavo M, Romito R, Collini P, Di Bartolomeo M, Fabbri A, Regalia E, Mazzaferro V. Resection versus transplantation for liver metastases from neuroendocrine tumors. *Transplant Proc* ; **33**: 1537-1539 [PMID: 11267413 DOI: 10.1016/S0041-1345(00)02586-0]

18 **Mayo SC**, de Jong MC, Pawlik TM. Surgical management and emerging therapies to prolong survival in metastatic neuroendocrine cancer. *Ann Surg Oncol* 2011; **18** Suppl 3: S220-S21; author reply S220-S21; [PMID: 20848222 DOI: 10.1245/s10434-010-1343-2]

19 **Saxena A**, Chua TC, Sarkar A, Chu F, Liauw W, Zhao J, Morris DL. Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. *Surgery* 2011; **149**: 209-220 [PMID: 20674950 DOI: 10.1016/j.surg.2010.06.008]

20 **Karabulut K**, Akyildiz HY, Lance C, Aucejo F, McLennan G, Agcaoglu O, Siperstein A, Berber E. Multimodality treatment of neuroendocrine liver metastases. *Surgery* 2011; **150**: 316-325 [PMID: 21801968 DOI: 10.1016/j.surg.2011.05.008]

21 **Glazer ES**, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, Abdalla EK, Vauthey JN, Curley SA. Long-term survival after surgical management of neuroendocrine hepatic metastases. *HPB (Oxford)* 2010; **12**: 427-433 [PMID: 20662794 DOI: 10.1111/j.1477-2574.2010.00198.x]

22 **Scigliano S**, Lebtahi R, Maire F, Stievenart JL, Kianmanesh R, Sauvanet A, Vullierme MP, Couvelard A, Belghiti J, Ruszniewski P, Le Guludec D. Clinical and imaging follow-up after exhaustive liver resection of endocrine metastases: a 15-year monocentric experience. *Endocr Relat Cancer* 2009; **16**: 977-990 [PMID: 19470616 DOI: 10.1677/ERC-08-0247]

23 **Fischer L**, Kleeff J, Esposito I, Hinz U, Zimmermann A, Friess H, Büchler MW. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. *Br J Surg* 2008; **95**: 627-635 [PMID: 18306152 DOI: 10.1002/bjs.6051]

24 **Kianmanesh R**, Sauvanet A, Hentic O, Couvelard A, Lévy P, Vilgrain V, Ruszniewski P, Belghiti J. Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. *Ann Surg* 2008; **247**: 659-665 [PMID: 18362629 DOI: 10.1097/SLA.0b013e31816a7061]

25 **Gomez D**, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. *HPB* (Oxford) 2007; **9**: 345-351 [PMID: 18345317 DOI: 10.1080/13651820701504199]

26 **Musunuru S**, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF, Weber SM. Metastatic neuroendocrine hepatic tumors: resection improves survival. *Arch Surg* 2006; **141**: 1000-104; discussion 1005 [PMID: 17043278 DOI: 10.1001/archsurg.141.10.1000]

27 **Touzios JG**, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA. Neuroendocrine hepatic metastases: does aggressive management improve survival? *Ann Surg* 2005; **241**: 776-83; discussion 783-5 [PMID: 15849513 DOI: 10.1097/01.sla.0000161981.58631.ab]

28 **Elias D**, Lasser P, Ducreux M, Duvillard P, Ouellet JF, Dromain C, Schlumberger M, Pocard M, Boige V, Miquel C, Baudin E. Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. *Surgery* 2003; **133**: 375-382 [PMID: 12717354 DOI: 10.1067/msy.2003.114]

29 **Mayo SC**, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, Celinksi SA, Kooby DA, Staley CA, Stokes JB, Chu CK, Ferrero A, Schulick RD, Choti MA, Mentha G, Strub J, Bauer TW, Adams RB, Aldrighetti L, Capussotti L, Pawlik TM. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. *Ann Surg Oncol* 2010; **17**: 3129-3136 [PMID: 20585879 DOI: 10.1245/s10434-010-1154-5]

30 **Bacchetti S**, Bertozzi S, Londero AP, Uzzau A, Pasqual EM. Surgical treatment and survival in patients with liver metastases from neuroendocrine tumors: a meta-analysis of observational studies. *Int J Hepatol* 2013; **2013**: 235040 [PMID: 23509630 DOI: 10.1155/2013/235040]

31 **Mayo SC**, Herman JM, Cosgrove D, Bhagat N, Kamel I, Geschwind JF, Pawlik TM. Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies. *J Am Coll Surg* 2013; **216**: 123-134 [PMID: 23063263 DOI: 10.1016/j.jamcollsurg.2012.08.027]

32 **Saxena A**, Chua TC, Zhao J, Morris DL. Liver-directed therapy for neuroendocrine neoplasm hepatic metastasis prolongs survival following progression after initial surgery. *J Surg Oncol* 2012; **105**: 342-350 [PMID: 22006355 DOI: 10.1002/jso.22114]

33 **Pathak S**, Dash I, Taylor MR, Poston GJ. The surgical management of neuroendocrine tumour hepatic metastases. *Eur J Surg Oncol* 2013; **39**: 224-228 [PMID: 23290582 DOI: 10.1016/j.ejso.2012.12.001]

34 **Marín C**, Robles R, Fernández JA, Bueno FS, Ramírez P, Miras M, Parrilla P. Role of liver transplantation in the management of unresectable neuroendocrine liver metastases. *Transplant Proc* 2007; **39**: 2302-2303 [PMID: 17889171 DOI: 10.1016/j.transproceed.2007.06.040]

35 **Lehnert T**. Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients. *Transplantation* 1998; **66**: 1307-1312 [PMID: 9846513 DOI: 10.1097/00007890-199811270-00007]

36 **Le Treut YP**, Grégoire E, Belghiti J, Boillot O, Soubrane O, Mantion G, Cherqui D, Castaing D, Ruszniewski P, Wolf P, Paye F, Salame E, Muscari F, Pruvot FR, Baulieux J. Predictors of long-term survival after liver transplantation for metastatic endocrine tumors: an 85-case French multicentric report. *Am J Transplant* 2008; **8**: 1205-1213 [PMID: 18444921 DOI: 10.1111/j.1600-6143.2008.02233.x]

37 **Máthé Z**, Tagkalos E, Paul A, Molmenti EP, Kóbori L, Fouzas I, Beckebaum S, Sotiropoulos GC. Liver transplantation for hepatic metastases of neuroendocrine pancreatic tumors: a survival-based analysis. *Transplantation* 2011; **91**: 575-582 [PMID: 21200365 DOI: 10.1097/TP.0b013e3182081312]

38 **Nguyen NT**, Harring TR, Goss JA, O'Mahony CA. Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation: The US Experience. *Int J Hepatol* 2011; **2011**: 742890 [PMID: 22254141 DOI: 10.4061/2011/742890]

39 **Mazzaferro V**, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? *J Hepatol* 2007; **47**: 460-466 [PMID: 17697723 DOI: 10.1016/j.jhep.2007.07.004]

40 **de Herder WW**, Mazzaferro V, Tavecchio L, Wiedenmann B. Multidisciplinary approach for the treatment of neuroendocrine tumors. *Tumori* ; **96**: 833-846 [PMID: 21302641]

41 **Olausson M**, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wängberg B, Ahlman H. Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors. *Liver Transpl* 2007; **13**: 327-333 [PMID: 17318853 DOI: 10.1002/lt.21056]

42 **van Vilsteren FG**, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. *Liver Transpl* 2006; **12**: 448-456 [PMID: 16498656 DOI: 10.1002/lt.20702]

43 **Taner T**, Atwell TD, Zhang L, Oberg TN, Harmsen WS, Slettedahl SW, Kendrick ML, Nagorney DM, Que FG. Adjunctive radiofrequency ablation of metastatic neuroendocrine cancer to the liver complements surgical resection. *HPB (Oxford)* 2013; **15**: 190-195 [PMID: 23374359 DOI: 10.1111/j.1477-2574.2012.00528.x]

44 **Akyildiz HY**, Mitchell J, Milas M, Siperstein A, Berber E. Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. *Surgery* 2010; **148**: 1288-193; discussion 1293 [PMID: 21134563 DOI: 10.1016/j.surg.2010.09.014]

45 **Martin RC**, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. *Ann Surg Oncol* 2010; **17**: 171-178 [PMID: 19707829 DOI: 10.1245/s10434-009-0686-z]

46 **Mazzaglia PJ**, Berber E, Milas M, Siperstein AE. Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. *Surgery* 2007; **142**: 10-19 [PMID: 17629995 DOI: 10.1016/j.surg.2007.01.036]

47 **Gillams A**, Cassoni A, Conway G, Lees W. Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience. *Abdom Imaging* ; **30**: 435-441 [PMID: 15759207 DOI: 10.1007/s00261-004-0258-4]

48 **Seifert JK**, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. *Semin Surg Oncol* 1998; **14**: 175-183 [PMID: 9492888 DOI: 10.1002/(SICI)1098-2388(199803)14: 2<175: : AID-SSU10>3.0.CO; 2-2]

49 **Shapiro RS**, Shafir M, Sung M, Warner R, Glajchen N. Cryotherapy of metastatic carcinoid tumors. *Abdom Imaging* ; **23**: 314-317 [PMID: 9569305 DOI: 10.1007/s002619900348]

50 **Bilchik AJ**, Sarantou T, Foshag LJ, Giuliano AE, Ramming KP. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. *Surgery* 1997; **122**: 1040-107; discussion 1040-107; [PMID: 9426418 DOI: 10.1016/S0039-6060(97)90207-5]

51 **Tait IS**, Yong SM, Cuschieri SA. Laparoscopic in situ ablation of liver cancer with cryotherapy and radiofrequency ablation. *Br J Surg* 2002; **89**: 1613-1619 [PMID: 12445075 DOI: 10.1046/j.1365-2168.2002.02264.x]

52 **Mayo SC**, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. *Cancer J* 2010; **16**: 111-117 [PMID: 20404607 DOI: 10.1097/PPO.0b013e3181d7ea07]

53 **Izzo F**. Other thermal ablation techniques: microwave and interstitial laser ablation of liver tumors. *Ann Surg Oncol* 2003; **10**: 491-497 [PMID: 12794014 DOI: 10.1245/ASO.2003.07.016]

54 **Livraghi T**, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. *Radiology* 2003; **226**: 441-451 [PMID: 12563138 DOI: 10.1148/radiol.2262012198]

55 **Shibata T**, Niinobu T, Ogata N. Comparison of the effects of in-vivo thermal ablation of pig liver by microwave and radiofrequency coagulation. *J Hepatobiliary Pancreat Surg* 2000; **7**: 592-598 [PMID: 11180892 DOI: 10.1007/s005340070009]

56 **Gravante G**, Ong SL, Metcalfe MS, Strickland A, Dennison AR, Lloyd DM. Hepatic microwave ablation: a review of the histological changes following thermal damage. *Liver Int* 2008; **28**: 911-921 [PMID: 18564212 DOI: 10.1111/j.1478-3231.2008.01810.x]

57 **Berber E**, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: an analysis of 1032 tumors. *Ann Surg Oncol* 2008; **15**: 2757-2764 [PMID: 18618182 DOI: 10.1245/s10434-008-0043-7]

58 **Paprottka PM**, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, Schmidt GP, Ashoori N, Reiser MF, Jakobs TF. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. *Cardiovasc Intervent Radiol* 2012; **35**: 334-342 [PMID: 21847708 DOI: 10.1007/s00270-011-0248-1]

59 **Dong XD**, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. *Med Oncol* 2011; **28** Suppl 1: S286-S290 [PMID: 21107755 DOI: 10.1007/s12032-010-9750-6]

60 **Saxena A**, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. *Ann Surg* 2010; **251**: 910-916 [PMID: 20395859 DOI: 10.1097/SLA.0b013e3181d3d24a]

61 **Cao CQ**, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. *Br J Surg* 2010; **97**: 537-543 [PMID: 20205229 DOI: 10.1002/bjs.6931]

62 **Kennedy AS**, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol* 2008; **31**: 271-279 [PMID: 18525307 DOI: 10.1097/COC.0b013e31815e4557]

63 **King J**, Quinn R, Glenn DM, Janssen J, Tong D, Liaw W, Morris DL. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer* 2008; **113**: 921-929 [PMID: 18618495 DOI: 10.1002/cncr.23685]

64 **Ho AS**, Picus J, Darcy MD, Tan B, Gould JE, Pilgram TK, Brown DB. Long-term outcome after chemoembolization and embolization of hepatic metastatic lesions from neuroendocrine tumors. *AJR Am J Roentgenol* 2007; **188**: 1201-1207 [PMID: 17449759 DOI: 10.2214/AJR.06.0933]

65 **Ruutiainen AT**, Soulen MC, Tuite CM, Clark TW, Mondschein JI, Stavropoulos SW, Trerotola SO. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. *J Vasc Interv Radiol* 2007; **18**: 847-855 [PMID: 17609443 DOI: 10.1016/j.jvir.2007.04.018]

66 **Strosberg JR**, Choi J, Cantor AB, Kvols LK. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. *Cancer Control* 2006; **13**: 72-78 [PMID: 16508629]

67 **Gupta S**, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, McRae SE, Hicks ME, Rao S, Vauthey JN, Ajani JA, Yao JC. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. *Cancer* 2005; **104**: 1590-1602 [PMID: 16134179 DOI: 10.1002/cncr.21389]

68 **Ruszniewski P**, Rougier P, Roche A, Legmann P, Sibert A, Hochlaf S, Ychou M, Mignon M. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. *Cancer* 1993; **71**: 2624-2630 [PMID: 8384072 DOI: 10.1002/1097-0142(19930415)71: 8<2624: : AID-CNCR2820710830>3.0.CO; 2-B]

69 **Ajani JA**, Carrasco CH, Charnsangavej C, Samaan NA, Levin B, Wallace S. Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. *Ann Intern Med* 1988; **108**: 340-344 [PMID: 2449109 DOI: 10.7326/0003-4819-108-3-340]

70 **Hajarizadeh H**, Ivancev K, Mueller CR, Fletcher WS, Woltering EA. Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy/chemoembolization combined with octreotide acetate. *Am J Surg* 1992; **163**: 479-483 [PMID: 1374222 DOI: 10.1016/0002-9610(92)90392-5]

71 **Perry LJ**, Stuart K, Stokes KR, Clouse ME. Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. *Surgery* 1994; **116**: 1111-116; discussion 1111-116; [PMID: 7985095]

72 **Toumpanakis C**, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. *Best Pract Res Clin Endocrinol Metab* 2007; **21**: 131-144 [PMID: 17382269 DOI: 10.1016/j.beem.2007.01.005]

73 **Christante D**, Pommier S, Givi B, Pommier R. Hepatic artery chemoinfusion with chemoembolization for neuroendocrine cancer with progressive hepatic metastases despite octreotide therapy. *Surgery* 2008; **144**: 885-93; discussion 893-4 [PMID: 19040993]

74 **Atassi B**, Bangash AK, Lewandowski RJ, Ibrahim S, Kulik L, Mulcahy MF, Murthy R, Ryu RK, Sato KT, Miller FH, Omary RA, Salem R. Biliary sequelae following radioembolization with Yttrium-90 microspheres. *J Vasc Interv Radiol* 2008; **19**: 691-697 [PMID: 18440457 DOI: 10.1016/j.jvir.2008.01.003]

75 **Liapi E**, Geschwind JF, Vossen JA, Buijs M, Georgiades CS, Bluemke DA, Kamel IR. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. *AJR Am J Roentgenol* 2008; **190**: 67-73 [PMID: 18094295 DOI: 10.2214/AJR.07.2550]

76 **Murthy R**, Kamat P, Nunez R, Madoff DC, Gupta S, Salem R, Yao JC. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. *J Vasc Interv Radiol* 2008; **19**: 145-151 [PMID: 18192482 DOI: 10.1016/j.jvir.2007.09.006]

77 **Rhee TK**, Lewandowski RJ, Liu DM, Mulcahy MF, Takahashi G, Hansen PD, Benson AB, Kennedy AS, Omary RA, Salem R. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. *Ann Surg* 2008; **247**: 1029-1035 [PMID: 18520231 DOI: 10.1097/SLA.0b013e3181728a45]

78 **Vogl TJ**, Gruber T, Naguib NN, Hammerstingl R, Nour-Eldin NE. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols. *AJR Am J Roentgenol* 2009; **193**: 941-947 [PMID: 19770314 DOI: 10.2214/AJR.08.1879]

79 **Vogl TJ**, Naguib NN, Zangos S, Eichler K, Hedayati A, Nour-Eldin NE. Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation. *Eur J Radiol* 2009; **72**: 517-528 [PMID: 18829195 DOI: 10.1016/j.ejrad.2008.08.008]

80 **Hentic O**, Couvelard A, Rebours V, Zappa M, Dokmak S, Hammel P, Maire F, O'Toole D, Lévy P, Sauvanet A, Ruszniewski P. Ki-67 index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas. *Endocr Relat Cancer* 2011; **18**: 51-59 [PMID: 20959440 DOI: 10.1677/ERC-09-0319]

81 **Jacobsen MB**, Hanssen LE. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial. *J Intern Med* 1995; **237**: 269-275 [PMID: 7534331 DOI: 10.1111/j.1365-2796.1995.tb01175.x]

82 **Imam H**, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs. *Acta Oncol* 1997; **36**: 607-614 [PMID: 9408151 DOI: 10.3109/02841869709001323]

83 **Aparicio T**, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. *Eur J Cancer* 2001; **37**: 1014-1019 [PMID: 11334727 DOI: 10.1016/S0959-8049(01)00073-9]

84 **Basuroy R**, Srirajaskanthan R, Ramage JK. A multimodal approach to the management of neuroendocrine tumour liver metastases. *Int J Hepatol* 2012; **2012**: 819193 [PMID: 22518323 DOI: 10.1155/2012/819193]

85 **Lewis MA,** Hobday TJ: Treatment of neuroendocrine tumor liver metastases. *Int J hepatol* 2012, **2012**: 973946 [PMID: 23227348 DOI: 10.1155/2012/973946]

86 **Ansell SM**, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. *Am J Clin Oncol* 2004; **27**: 232-235 [PMID: 15170140 DOI: 10.1097/01.COC.0000054535.19808.F4]

87 **Ramanathan RK**, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. *Ann Oncol* 2001; **12**: 1139-1143 [PMID: 11583197 DOI: 10.1023/A: 1011632713360]

88 **Moertel CG**, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. *N Engl J Med* 1980; **303**: 1189-1194 [PMID: 6252466 DOI: 10.1056/NEJM198011203032101]

89 **Moertel CG**, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. *Cancer* 1991; **68**: 227-232 [PMID: 1712661 DOI: 3.0.CO; 2-I']

90 **Strosberg JR**, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. *Cancer* 2011; **117**: 268-275 [PMID: 20824724 DOI: 10.1002/cncr.25425]

91 **Delaunoit T**, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E. The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? *Eur J Cancer* 2004; **40**: 515-520 [PMID: 14962717 DOI: 10.1016/j.ejca.2003.09.035]

92 **Ekeblad S**, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Kozlovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. *Clin Cancer Res* 2007; **13**: 2986-2991 [PMID: 17505000 DOI: 10.1158/1078-0432.CCR-06-2053]

93 **Engstrom PF**, Lavin PT, Moertel CG, Folsch E, Douglass HO. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. *J Clin Oncol* 1984; **2**: 1255-1259 [PMID: 6238136]

94 **Faiss S**, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, Riecken EO, Wiedenmann B. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. *J Clin Oncol* 2003; **21**: 2689-2696 [PMID: 12860945 DOI: 10.1200/JCO.2003.12.142]

95 **Fazio N**, de Braud F, Delle Fave G, Oberg K. Interferon-alpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? *Ann Oncol* 2007; **18**: 13-19 [PMID: 16798833 DOI: 10.1093/annonc/mdl144]

96 **Gonzalez MA**, Biswas S, Clifton L, Corrie PG. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. *Br J Cancer* 2003; **89**: 455-456 [PMID: 12888810 DOI: 10.1038/sj.bjc.6601167]

97 **Kulke MH**, Kim H, Clark JW, Enzinger PC, Lynch TJ, Morgan JA, Vincitore M, Michelini A, Fuchs CS. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. *Cancer* 2004; **101**: 934-939 [PMID: 15329900 DOI: 10.1002/cncr.20466]

98 **Kulke MH**, Kim H, Stuart K, Clark JW, Ryan DP, Vincitore M, Mayer RJ, Fuchs CS. A phase II study of docetaxel in patients with metastatic carcinoid tumors. *Cancer Invest* 2004; **22**: 353-359 [PMID: 15493355 DOI: 10.1081/CNV-200029058]

99 **Claringbold PG**, Brayshaw PA, Price RA, Turner JH. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. *Eur J Nucl Med Mol Imaging* 2011; **38**: 302-311 [PMID: 21052661 DOI: 10.1007/s00259-010-1631-x]

100 **Cwikla JB**, Sankowski A, Seklecka N, Buscombe JR, Nasierowska-Guttmejer A, Jeziorski KG, Mikolajczak R, Pawlak D, Stepien K, Walecki J. Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study. *Ann Oncol* 2010; **21**: 787-794 [PMID: 19833821 DOI: 10.1093/annonc/mdp372]

101 **Bruska M**. Migration zone during the development of the trigeminal motor nucleus. Part II. Embryos at developmental stages 18 to 23. *Folia Morphol* (Warsz) 1991; **50**: 119-125 [PMID: 1844584 DOI: 10.1200/JCO.2007.15.2553]

102 **Kwekkeboom DJ**, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, van Eijck CH, Esser JP, Kam BL, Krenning EP. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. *J Clin Oncol* 2005; **23**: 2754-2762 [PMID: 15837990 DOI: 10.1200/JCO.2005.08.066]

103 **Miederer M**, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, Essler M. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. *Clin Cancer Res* 2008; **14**: 3555-3561 [PMID: 18519789 DOI: 10.1158/1078-0432.CCR-07-4647]

104 **Nayak TK**, Atcher RW, Prossnitz ER, Norenberg JP. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation. *Nucl Med Biol* 2008; **35**: 673-678 [PMID: 18678352 DOI: 10.1016/j.nucmedbio.2008.05.003]

105 **Pfeifer AK**, Gregersen T, Grønbæk H, Hansen CP, Müller-Brand J, Herskind Bruun K, Krogh K, Kjær A, Knigge U. Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. *Neuroendocrinology* 2011; **93**: 189-196 [PMID: 21335949 DOI: 10.1159/000324096]

106 **Raymond E**, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011; **364**: 501-513 [PMID: 21306237 DOI: 10.1056/NEJMoa1003825]

107 **Safford SD**, Coleman RE, Gockerman JP, Moore J, Feldman J, Onaitis MW, Tyler DS, Olson JA. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. *Cancer* 2004; **101**: 1987-1993 [PMID: 15455358 DOI: 10.1002/cncr.20592]

108 **Takeuchi S**, Honma R, Taguchi J, Amano T, Shimizu Y, Kinoshita I, Kubota K, Matsuno Y, Dosaka-Akita H. A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy. *Case Rep Oncol* 2011; **4**: 260-266 [PMID: 21734880 DOI: 10.1159/000328802]

109 **Gilbert JA**, Adhikari LJ, Lloyd RV, Rubin J, Haluska P, Carboni JM, Gottardis MM, Ames MM. Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors. *Endocr Relat Cancer* 2010; **17**: 623-636 [PMID: 20385747 DOI: 10.1677/ERC-09-0318]

110 **Yao JC**, Hoff PM. Molecular targeted therapy for neuroendocrine tumors. *Hematol Oncol Clin North Am* 2007; **21**: 575-81; x [PMID: 17548041 DOI: 10.1016/j.hoc.2007.04.001]

111 **Yao JC**, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. *J Clin Oncol* 2008; **26**: 1316-1323 [PMID: 18323556 DOI: 10.1200/JCO.2007.13.6374]

112 **Yao JC**, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011; **364**: 514-523 [PMID: 21306238 DOI: 10.1056/NEJMoa1009290]

**P-Reviewers: Gong Y, Welling TH S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Comparison of outcomes**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Labels** | **Publication year** | **Number of patients LR/Other** | **5 yr OS LR/Other** | **Median Survival** |
| **LR/Other (mo)** |
| Liver resection *vs* no Liver resection |  |  |  |  |
| Soreide *et al*[11] | 1992 | 36/39 |  | 216/48 |
| Chen *et al*[12] | 1998 | 15/23 | 73%/29% | 1/27 |
| Grazi *et al*[7] | 2000 | 9/19 | 92.6%/18.5%2 |  |
| Ahmed *et al*[13] | 2009 | 50/310 | 78%/52% | 135/66 |
| Surgery *vs* Ablation |  |  |  |  |
| Yao *et al*[14] | 2001 | 16/20 | 70%/40% | 3/32 |
| Osborne *et al*[15] | 2006 | 38 Complete and 23 palliative/53 | 78% and 64%/35% | 50 ± 27.6 /32 ± 18.9 |
| Surgery *vs* Intra-arterial therapy |  |  |  |  |
| Mayo *et al*[16] | 2011 | 339/414 | 74%/30% | 123/34 |
| Surgery *vs* Transplantation |  |  |  |  |
| Coppa *et al*[17] | 2001 | 9/20 | 67%/70% | 29%/53% |
| Surgical resection |  |  |  |  |
| Mayo *et al*[18] | 2011 | Resection +/- Ablation (66 simultaneous ablation) | 339 |  |
| Saxena *et al*[19] | 2011 | Resection +/- Ablation | 74 |  |
| Karabulut *et al*[20] | 2011 | Resection | 27 |  |
| Glazer *et al*[21] | 2010 | Resection +/- Ablation (18 Patients only RFA) | 172 | 77.40% |
| Scigliano *et al*[22] | 2009 | Resection | 41 | 79% |
| Fischer *et al*[23] | 2008 | Resection | 118 | 44% |
| Kianmanesh *et al*[24] | 2008 | Resection | 23 | 94% |
| Gomez *et al*[25] | 2007 | Resection | 18 | 86% |
| Osborne *et al*[15] | 2006 | Cytoreduction | 70 |  |
| Musunuru *et al*[26] | 2006 | Resection +/- Ablation | 13 | 83%6 |
| Touzios *et al*[27] | 2005 | Resection +/- Ablation | 18 | 72% |
| Sarmiento *et al*[2] | 2003 | Complete resection in 70 patients | 170 | 61% |
| Elias *et al*[28] | 2003 | Resection and 36 with concurrent extrahepatic resection | 47 | 71% |
| Mazzaferro *et al*[17] | 2001 | Resection | 20 | 67% |
| Grazi *et al*[7] | 2000 | Resection | 19 | 92%5 |
| Chen *et al*[12] | 1998 | Resection | 15 | 73% |

1Median survival not reached during the study period; 24 year survival; 3Median survival not reached during the study period; 4Mean survival; 54 year survival; 63 year survival.

**Table 2 Comparison of outcomes of liver transplantation**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **First Author** | **Publication Year** | **Number of Patients** | **Overall Survival (5 yr)** | **Progression/Disease free survival (5 yr)** |
| ELTR *et al*[10] | (1982-2009) | 213 | 52% | 30% |
| (2000-2009) | 106 | 59% | 39% |
| N’Guyen *et al*[38] | (1988-2011) | 184 | 49% |  |
| (2002-2011) | 110 | 58% |  |
| Gedaly *et al*[9] | 2011 | 150 | 49% | 32% |
| Mathe *et al*[37] | 2011 | 89 | 44% |  |
| Le treut *et al*[36] | 2008 | 85 | 47% |  |
| Lehnert *et al*[35] | 1998 | 103 | 47% |  |

**Table 3 Comparison of outcomes of ablative techniques**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **First author** | **Publication year** | **Mode of Therapy** | **Number of patients**  **ablated** | **Median PFS** | **Median OS** |
| Nagorney *et al*[43] | 2012 | RFA and extra-hepatic resection | 94 | 24 mo |  |
| Karabulut *et al*[20] | 2011 | RFA | 69 | 10.5 mo | 73 mo |
| Akyilidiz *et al*[44] | 2010 | RFA | 30 | 15.6 mo | 72 mo |
| Martin *et al*[45] | 2010 | MWA and extra-hepatic resection | 11 | 8 mo | 18 mo |
| Mazzaglia *et al*[46] | 2007 | RFA and extra-hepatic resection | 63 |  | 47 mo |
| Gilliams *et al*[47] | 2005 | RFA | 25 |  | 29 mo |
| Seifert *et al*[48] | 1998 | Cryotherapy | 13 |  | 103 mo |
| Shapiro *et al*[49] | 1998 | Cryotherapy | 5 | 1 |  |
| Bilchik *et al*[50] | 1997 | Cryotherapy | 19 | 10 mo | 49 mo |

1 Mean follow-up 2.5 years, Overall survival 20%.

**Table 4 Comparison of outcomes of Intra-arterial therapies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **First Author** | **Publication year** | **Mode of Therapy** | **Number of patients ablated** | **Median PFS** | **Median OS** |
| Paprottka *et al*[58] | 2011 | RE | 42 | 1 |  |
| Dong *et al*[59] | 2011 | HACE | 123 |  | 40 mo |
| Saxena *et al*[60] | 2010 | RE | 48 |  | 35 mo |
| Cao *et al*[61] | 2010 | RE | 58 |  | 36 mo |
| Kennedy *et al*[62] | 2008 | RE | 148 |  | 70 mo |
| King *et al*[63] | 2008 | RE | 37 |  | 29 mo |
| Ho *et al*[64] | 2007 | HAE/HACE | 46 | 18 mo | 42 mo |
| Ruutiainen *et al*[65] | 2007 | HACE | 57 | 36 mo |  |
| Strosberg *et al*[66] | 2006 | HAE | 84 |  | 36 mo |
| Gupta *et al*[67] | 2005 | HAE/HACE | 123  74 HAE  49 HACE | 22 mo  16 mo | 34 mo  23 mo |
| Pitt *et al*[27] | 2008 | HAE/HACE | 100  51 HAE  49 HACE |  | 25.5 mo  25.7 mo |
| Ruszniewski *et al*[68] | 1993 | HACE | 24 | 14 mo |  |

1Mean follow up 16. 2 mo, 95.2% alive.